The University of Southampton
University of Southampton Institutional Repository

Global, regional, and national burden of diabetes from 1990 to 2021, with projections of prevalence to 2050: a systematic analysis for the Global Burden of Disease Study 2021

Global, regional, and national burden of diabetes from 1990 to 2021, with projections of prevalence to 2050: a systematic analysis for the Global Burden of Disease Study 2021
Global, regional, and national burden of diabetes from 1990 to 2021, with projections of prevalence to 2050: a systematic analysis for the Global Burden of Disease Study 2021

Background: diabetes is one of the leading causes of death and disability worldwide, and affects people regardless of country, age group, or sex. Using the most recent evidentiary and analytical framework from the Global Burden of Diseases, Injuries, and Risk Factors Study (GBD), we produced location-specific, age-specific, and sex-specific estimates of diabetes prevalence and burden from 1990 to 2021, the proportion of type 1 and type 2 diabetes in 2021, the proportion of the type 2 diabetes burden attributable to selected risk factors, and projections of diabetes prevalence through 2050. 

Methods: estimates of diabetes prevalence and burden were computed in 204 countries and territories, across 25 age groups, for males and females separately and combined; these estimates comprised lost years of healthy life, measured in disability-adjusted life-years (DALYs; defined as the sum of years of life lost [YLLs] and years lived with disability [YLDs]). We used the Cause of Death Ensemble model (CODEm) approach to estimate deaths due to diabetes, incorporating 25 666 location-years of data from vital registration and verbal autopsy reports in separate total (including both type 1 and type 2 diabetes) and type-specific models. Other forms of diabetes, including gestational and monogenic diabetes, were not explicitly modelled. Total and type 1 diabetes prevalence was estimated by use of a Bayesian meta-regression modelling tool, DisMod-MR 2.1, to analyse 1527 location-years of data from the scientific literature, survey microdata, and insurance claims; type 2 diabetes estimates were computed by subtracting type 1 diabetes from total estimates. Mortality and prevalence estimates, along with standard life expectancy and disability weights, were used to calculate YLLs, YLDs, and DALYs. When appropriate, we extrapolated estimates to a hypothetical population with a standardised age structure to allow comparison in populations with different age structures. We used the comparative risk assessment framework to estimate the risk-attributable type 2 diabetes burden for 16 risk factors falling under risk categories including environmental and occupational factors, tobacco use, high alcohol use, high body-mass index (BMI), dietary factors, and low physical activity. Using a regression framework, we forecast type 1 and type 2 diabetes prevalence through 2050 with Socio-demographic Index (SDI) and high BMI as predictors, respectively. 

Findings: in 2021, there were 529 million (95% uncertainty interval [UI] 500–564) people living with diabetes worldwide, and the global age-standardised total diabetes prevalence was 6·1% (5·8–6·5). At the super-region level, the highest age-standardised rates were observed in north Africa and the Middle East (9·3% [8·7–9·9]) and, at the regional level, in Oceania (12·3% [11·5–13·0]). Nationally, Qatar had the world's highest age-specific prevalence of diabetes, at 76·1% (73·1–79·5) in individuals aged 75–79 years. Total diabetes prevalence—especially among older adults—primarily reflects type 2 diabetes, which in 2021 accounted for 96·0% (95·1–96·8) of diabetes cases and 95·4% (94·9–95·9) of diabetes DALYs worldwide. In 2021, 52·2% (25·5–71·8) of global type 2 diabetes DALYs were attributable to high BMI. The contribution of high BMI to type 2 diabetes DALYs rose by 24·3% (18·5–30·4) worldwide between 1990 and 2021. By 2050, more than 1·31 billion (1·22–1·39) people are projected to have diabetes, with expected age-standardised total diabetes prevalence rates greater than 10% in two super-regions: 16·8% (16·1–17·6) in north Africa and the Middle East and 11·3% (10·8–11·9) in Latin America and Caribbean. By 2050, 89 (43·6%) of 204 countries and territories will have an age-standardised rate greater than 10%. 

Interpretation: diabetes remains a substantial public health issue. Type 2 diabetes, which makes up the bulk of diabetes cases, is largely preventable and, in some cases, potentially reversible if identified and managed early in the disease course. However, all evidence indicates that diabetes prevalence is increasing worldwide, primarily due to a rise in obesity caused by multiple factors. Preventing and controlling type 2 diabetes remains an ongoing challenge. It is essential to better understand disparities in risk factor profiles and diabetes burden across populations, to inform strategies to successfully control diabetes risk factors within the context of multiple and complex drivers. Funding: Bill & Melinda Gates Foundation.

0140-6736
203-234
Ong, Kanyin Liane
92828e1b-c600-4a32-87fb-6008f49bf7f0
Stafford, Lauryn K.
fd83a70a-3dcc-4c44-a344-960b24dbbc0e
McLaughlin, Susan A.
8d938c72-82df-49e2-9cea-8365e32e3a9e
Boyko, Edward J.
c8b232a3-663e-4356-9c4e-b94fab7f2456
Vollset, Stein Emil
d540cc42-aa8e-4648-b023-82e6b34b7e25
Smith, Amanda E.
7e97a825-9e3a-43fa-8c30-e2bcce07a41c
Dalton, Bronte E.
fc2d1345-ef31-4d7d-9c05-c91a8e4c19df
Duprey, Joe
8365ce40-cc59-47bc-a397-a943664e7de7
Cruz, Jessica A.
9de02cc3-2ecf-4590-b96d-4ef5a1a1ebc3
Hagins, Hailey
a4a0941d-4bd8-40bd-a422-daa3c55a20e0
Lindstedt, Paulina A.
0ded3c0d-68e3-4e9d-baea-ddb80e1f3947
Aali, Amirali
1b689997-e8b2-454b-9ca7-4b7837d85aba
Abate, Yohannes Habtegiorgis
e872bcc3-7ac0-4df4-8dd9-a865ef956360
Abate, Melsew Dagne
b0705980-bd89-4ada-a344-e015f5029cc3
Abbasian, Mohammadreza
afc38c7a-6864-4a98-9aaa-ed4d60255d50
Abbasi-Kangevari, Zeinab
24d7e519-3191-4995-b079-589b3fa796b5
Abbasi-Kangevari, Mohsen
6605d315-6856-461b-a501-4a38e4ab9918
ElHafeez, Samar Abd
00ce946e-3cde-47a7-b8a7-06a79bf86d19
Abd-Rabu, Rami
1437731b-fff5-4c40-8a8e-97cc96608a5a
Abdulah, Deldar Morad
ba219b1d-1c4b-4cdd-a4ad-5eea1825ab4f
Abdullah, Abu Yousuf Md
5d843dcf-963a-42cb-8aac-f288328f9024
Abedi, Vida
bbd38477-d340-4373-bf2e-98657083efbf
Abidi, Hassan
a6917f46-ebcf-4fd6-86b2-f11394bc6589
Aboagye, Richard Gyan
39ff1fbb-870b-4372-a409-6d640fd9282b
Abolhassani, Hassan
f02011b5-df85-4627-94c7-1365a4241b95
Abu-Gharbieh, Eman
213c5b0f-c0cc-4b7c-a077-35586359cf01
Abu-Zaid, Ahmed
0176f58d-7aec-4154-8085-50a0495bcdc5
Adane, Tigist Demssew
0f2ad7b3-a913-4b26-9e3f-d5189bb7d719
Adane, Denberu Eshetie
25cdcb76-6619-443c-9baf-150d3c855fdf
Addo, Isaac Yeboah
e3c9439f-928b-4436-ad41-bd78f570831c
Adegboye, Oyelola A.
4c0e5f72-02bc-4b43-ad1e-ba27da59d747
Adekanmbi, Victor
46d212c3-bfe7-468e-8f11-0574bbbb90bd
Adepoju, Abiola Victor
cdeeb259-2999-4c8a-bb59-ebfe2b569a35
Adnani, Qorinah Estiningtyas Sakilah
00601077-d3be-49d0-a66d-98aa9330966e
Afolabi, Rotimi Felix
c67620dc-752f-4157-83be-db4087309442
Agarwal, Gina
857b681f-eb3d-44a7-8f21-1ade6a01a9cc
Aghdam, Zahra Babaei
3f45a91b-ee79-4cc7-9323-012be097bef0
Lee, Wei Chen
2c7e8688-12f7-4f8a-a3df-0844ba1925fb
Lee, Paul H.
02620eab-ae7f-4a1c-bad1-8a50e7e48951
Lee, Seung Won
0bd48c08-fc42-4dfc-b1a8-2ee0321e2ae7
Li, Ming Chieh
e7b70af5-2e07-4c8c-b15e-6840a7e0ef74
Lim, Stephen S.
490f1a74-6582-468a-a0ba-03d3216f3531
Moniruzzaman, Md
c05dc7e4-b2c0-4f42-9035-4806ee0e250c
Rahman, Mohammad Hifz Ur
b92d45f5-e446-40ad-9c53-b3a18a781a87
Rahman, Md Mosfequr
afe5e395-b463-4ffd-8fe0-bd3ddbc60733
Salomon, Joshua A.
0b7704e4-824d-434f-8e09-0fee359262e7
Verras, Georgios Ioannis
1e3f8f28-8d57-42e0-b097-b69d0170f61f
Wang, Fang
da66eff5-d86a-4a00-ba01-ab0a2765522a
Wu, Yi Fan
01937f99-c2f4-4049-9d94-ed5622c17525
Zhang, Zhi Jiang
bdebb5a0-7c3d-420e-903b-276e5b0c1a25
GBD 2021 Diabetes Collaborators
Ong, Kanyin Liane
92828e1b-c600-4a32-87fb-6008f49bf7f0
Stafford, Lauryn K.
fd83a70a-3dcc-4c44-a344-960b24dbbc0e
McLaughlin, Susan A.
8d938c72-82df-49e2-9cea-8365e32e3a9e
Boyko, Edward J.
c8b232a3-663e-4356-9c4e-b94fab7f2456
Vollset, Stein Emil
d540cc42-aa8e-4648-b023-82e6b34b7e25
Smith, Amanda E.
7e97a825-9e3a-43fa-8c30-e2bcce07a41c
Dalton, Bronte E.
fc2d1345-ef31-4d7d-9c05-c91a8e4c19df
Duprey, Joe
8365ce40-cc59-47bc-a397-a943664e7de7
Cruz, Jessica A.
9de02cc3-2ecf-4590-b96d-4ef5a1a1ebc3
Hagins, Hailey
a4a0941d-4bd8-40bd-a422-daa3c55a20e0
Lindstedt, Paulina A.
0ded3c0d-68e3-4e9d-baea-ddb80e1f3947
Aali, Amirali
1b689997-e8b2-454b-9ca7-4b7837d85aba
Abate, Yohannes Habtegiorgis
e872bcc3-7ac0-4df4-8dd9-a865ef956360
Abate, Melsew Dagne
b0705980-bd89-4ada-a344-e015f5029cc3
Abbasian, Mohammadreza
afc38c7a-6864-4a98-9aaa-ed4d60255d50
Abbasi-Kangevari, Zeinab
24d7e519-3191-4995-b079-589b3fa796b5
Abbasi-Kangevari, Mohsen
6605d315-6856-461b-a501-4a38e4ab9918
ElHafeez, Samar Abd
00ce946e-3cde-47a7-b8a7-06a79bf86d19
Abd-Rabu, Rami
1437731b-fff5-4c40-8a8e-97cc96608a5a
Abdulah, Deldar Morad
ba219b1d-1c4b-4cdd-a4ad-5eea1825ab4f
Abdullah, Abu Yousuf Md
5d843dcf-963a-42cb-8aac-f288328f9024
Abedi, Vida
bbd38477-d340-4373-bf2e-98657083efbf
Abidi, Hassan
a6917f46-ebcf-4fd6-86b2-f11394bc6589
Aboagye, Richard Gyan
39ff1fbb-870b-4372-a409-6d640fd9282b
Abolhassani, Hassan
f02011b5-df85-4627-94c7-1365a4241b95
Abu-Gharbieh, Eman
213c5b0f-c0cc-4b7c-a077-35586359cf01
Abu-Zaid, Ahmed
0176f58d-7aec-4154-8085-50a0495bcdc5
Adane, Tigist Demssew
0f2ad7b3-a913-4b26-9e3f-d5189bb7d719
Adane, Denberu Eshetie
25cdcb76-6619-443c-9baf-150d3c855fdf
Addo, Isaac Yeboah
e3c9439f-928b-4436-ad41-bd78f570831c
Adegboye, Oyelola A.
4c0e5f72-02bc-4b43-ad1e-ba27da59d747
Adekanmbi, Victor
46d212c3-bfe7-468e-8f11-0574bbbb90bd
Adepoju, Abiola Victor
cdeeb259-2999-4c8a-bb59-ebfe2b569a35
Adnani, Qorinah Estiningtyas Sakilah
00601077-d3be-49d0-a66d-98aa9330966e
Afolabi, Rotimi Felix
c67620dc-752f-4157-83be-db4087309442
Agarwal, Gina
857b681f-eb3d-44a7-8f21-1ade6a01a9cc
Aghdam, Zahra Babaei
3f45a91b-ee79-4cc7-9323-012be097bef0
Lee, Wei Chen
2c7e8688-12f7-4f8a-a3df-0844ba1925fb
Lee, Paul H.
02620eab-ae7f-4a1c-bad1-8a50e7e48951
Lee, Seung Won
0bd48c08-fc42-4dfc-b1a8-2ee0321e2ae7
Li, Ming Chieh
e7b70af5-2e07-4c8c-b15e-6840a7e0ef74
Lim, Stephen S.
490f1a74-6582-468a-a0ba-03d3216f3531
Moniruzzaman, Md
c05dc7e4-b2c0-4f42-9035-4806ee0e250c
Rahman, Mohammad Hifz Ur
b92d45f5-e446-40ad-9c53-b3a18a781a87
Rahman, Md Mosfequr
afe5e395-b463-4ffd-8fe0-bd3ddbc60733
Salomon, Joshua A.
0b7704e4-824d-434f-8e09-0fee359262e7
Verras, Georgios Ioannis
1e3f8f28-8d57-42e0-b097-b69d0170f61f
Wang, Fang
da66eff5-d86a-4a00-ba01-ab0a2765522a
Wu, Yi Fan
01937f99-c2f4-4049-9d94-ed5622c17525
Zhang, Zhi Jiang
bdebb5a0-7c3d-420e-903b-276e5b0c1a25

GBD 2021 Diabetes Collaborators (2023) Global, regional, and national burden of diabetes from 1990 to 2021, with projections of prevalence to 2050: a systematic analysis for the Global Burden of Disease Study 2021. The Lancet, 402 (10397), 203-234. (doi:10.1016/S0140-6736(23)01301-6).

Record type: Article

Abstract

Background: diabetes is one of the leading causes of death and disability worldwide, and affects people regardless of country, age group, or sex. Using the most recent evidentiary and analytical framework from the Global Burden of Diseases, Injuries, and Risk Factors Study (GBD), we produced location-specific, age-specific, and sex-specific estimates of diabetes prevalence and burden from 1990 to 2021, the proportion of type 1 and type 2 diabetes in 2021, the proportion of the type 2 diabetes burden attributable to selected risk factors, and projections of diabetes prevalence through 2050. 

Methods: estimates of diabetes prevalence and burden were computed in 204 countries and territories, across 25 age groups, for males and females separately and combined; these estimates comprised lost years of healthy life, measured in disability-adjusted life-years (DALYs; defined as the sum of years of life lost [YLLs] and years lived with disability [YLDs]). We used the Cause of Death Ensemble model (CODEm) approach to estimate deaths due to diabetes, incorporating 25 666 location-years of data from vital registration and verbal autopsy reports in separate total (including both type 1 and type 2 diabetes) and type-specific models. Other forms of diabetes, including gestational and monogenic diabetes, were not explicitly modelled. Total and type 1 diabetes prevalence was estimated by use of a Bayesian meta-regression modelling tool, DisMod-MR 2.1, to analyse 1527 location-years of data from the scientific literature, survey microdata, and insurance claims; type 2 diabetes estimates were computed by subtracting type 1 diabetes from total estimates. Mortality and prevalence estimates, along with standard life expectancy and disability weights, were used to calculate YLLs, YLDs, and DALYs. When appropriate, we extrapolated estimates to a hypothetical population with a standardised age structure to allow comparison in populations with different age structures. We used the comparative risk assessment framework to estimate the risk-attributable type 2 diabetes burden for 16 risk factors falling under risk categories including environmental and occupational factors, tobacco use, high alcohol use, high body-mass index (BMI), dietary factors, and low physical activity. Using a regression framework, we forecast type 1 and type 2 diabetes prevalence through 2050 with Socio-demographic Index (SDI) and high BMI as predictors, respectively. 

Findings: in 2021, there were 529 million (95% uncertainty interval [UI] 500–564) people living with diabetes worldwide, and the global age-standardised total diabetes prevalence was 6·1% (5·8–6·5). At the super-region level, the highest age-standardised rates were observed in north Africa and the Middle East (9·3% [8·7–9·9]) and, at the regional level, in Oceania (12·3% [11·5–13·0]). Nationally, Qatar had the world's highest age-specific prevalence of diabetes, at 76·1% (73·1–79·5) in individuals aged 75–79 years. Total diabetes prevalence—especially among older adults—primarily reflects type 2 diabetes, which in 2021 accounted for 96·0% (95·1–96·8) of diabetes cases and 95·4% (94·9–95·9) of diabetes DALYs worldwide. In 2021, 52·2% (25·5–71·8) of global type 2 diabetes DALYs were attributable to high BMI. The contribution of high BMI to type 2 diabetes DALYs rose by 24·3% (18·5–30·4) worldwide between 1990 and 2021. By 2050, more than 1·31 billion (1·22–1·39) people are projected to have diabetes, with expected age-standardised total diabetes prevalence rates greater than 10% in two super-regions: 16·8% (16·1–17·6) in north Africa and the Middle East and 11·3% (10·8–11·9) in Latin America and Caribbean. By 2050, 89 (43·6%) of 204 countries and territories will have an age-standardised rate greater than 10%. 

Interpretation: diabetes remains a substantial public health issue. Type 2 diabetes, which makes up the bulk of diabetes cases, is largely preventable and, in some cases, potentially reversible if identified and managed early in the disease course. However, all evidence indicates that diabetes prevalence is increasing worldwide, primarily due to a rise in obesity caused by multiple factors. Preventing and controlling type 2 diabetes remains an ongoing challenge. It is essential to better understand disparities in risk factor profiles and diabetes burden across populations, to inform strategies to successfully control diabetes risk factors within the context of multiple and complex drivers. Funding: Bill & Melinda Gates Foundation.

Text
PIIS0140673623013016 - Version of Record
Available under License Creative Commons Attribution.
Download (7MB)

More information

e-pub ahead of print date: 15 July 2023
Published date: 15 July 2023

Identifiers

Local EPrints ID: 499525
URI: http://eprints.soton.ac.uk/id/eprint/499525
ISSN: 0140-6736
PURE UUID: 78ebfd73-e4dc-4d71-b71f-673b08a20a99
ORCID for Paul H. Lee: ORCID iD orcid.org/0000-0002-5729-6450

Catalogue record

Date deposited: 24 Mar 2025 17:59
Last modified: 22 Aug 2025 02:37

Export record

Altmetrics

Contributors

Author: Kanyin Liane Ong
Author: Lauryn K. Stafford
Author: Susan A. McLaughlin
Author: Edward J. Boyko
Author: Stein Emil Vollset
Author: Amanda E. Smith
Author: Bronte E. Dalton
Author: Joe Duprey
Author: Jessica A. Cruz
Author: Hailey Hagins
Author: Paulina A. Lindstedt
Author: Amirali Aali
Author: Yohannes Habtegiorgis Abate
Author: Melsew Dagne Abate
Author: Mohammadreza Abbasian
Author: Zeinab Abbasi-Kangevari
Author: Mohsen Abbasi-Kangevari
Author: Samar Abd ElHafeez
Author: Rami Abd-Rabu
Author: Deldar Morad Abdulah
Author: Abu Yousuf Md Abdullah
Author: Vida Abedi
Author: Hassan Abidi
Author: Richard Gyan Aboagye
Author: Hassan Abolhassani
Author: Eman Abu-Gharbieh
Author: Ahmed Abu-Zaid
Author: Tigist Demssew Adane
Author: Denberu Eshetie Adane
Author: Isaac Yeboah Addo
Author: Oyelola A. Adegboye
Author: Victor Adekanmbi
Author: Abiola Victor Adepoju
Author: Qorinah Estiningtyas Sakilah Adnani
Author: Rotimi Felix Afolabi
Author: Gina Agarwal
Author: Zahra Babaei Aghdam
Author: Wei Chen Lee
Author: Paul H. Lee ORCID iD
Author: Seung Won Lee
Author: Ming Chieh Li
Author: Stephen S. Lim
Author: Md Moniruzzaman
Author: Mohammad Hifz Ur Rahman
Author: Md Mosfequr Rahman
Author: Joshua A. Salomon
Author: Georgios Ioannis Verras
Author: Fang Wang
Author: Yi Fan Wu
Author: Zhi Jiang Zhang
Corporate Author: GBD 2021 Diabetes Collaborators

Download statistics

Downloads from ePrints over the past year. Other digital versions may also be available to download e.g. from the publisher's website.

View more statistics

Atom RSS 1.0 RSS 2.0

Contact ePrints Soton: eprints@soton.ac.uk

ePrints Soton supports OAI 2.0 with a base URL of http://eprints.soton.ac.uk/cgi/oai2

This repository has been built using EPrints software, developed at the University of Southampton, but available to everyone to use.

We use cookies to ensure that we give you the best experience on our website. If you continue without changing your settings, we will assume that you are happy to receive cookies on the University of Southampton website.

×